Glycoprotein IIb/IIIa receptor inhibitors in percutaneous coronary intervention and acute coronary syndrome

Annals of Pharmacotherapy

Volumn 37, Issue 6, 2003, Pages 860-875

  Crouch, Michael A ^a   Nappi, Jean M ^b   Cheang, Kai I ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Abciximab; Acute coronary syndrome; Eptifibatide; Glycoprotein IIb IIIa receptor inhibitors; Percutaneous coronary intervention; Tirofiban

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; RETEPLASE; TENECTEPLASE; THROMBIN INHIBITOR; TICLOPIDINE; TIROFIBAN;

ACUTE HEART INFARCTION; ANGINA PECTORIS; ATHERECTOMY; BLEEDING; BRAIN HEMORRHAGE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; FEMALE; FIBRINOLYSIS; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDLINE; META ANALYSIS; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR BLOCKING; REVIEW; RISK ASSESSMENT; ST SEGMENT ELEVATION; THROMBOCYTOPENIA; UNSTABLE ANGINA PECTORIS;

ANIMALS; ANTICOAGULANTS; ATHERECTOMY; CLINICAL TRIALS; CORONARY DISEASE; HUMANS; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX;

EID: 0038823914     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1C338     Document Type: Review

References (81)

1. Coller BS. Monitoring platelet GP IIb/IIIa antagonist therapy. Circulation 1997;96:3828-32.
2. Chew DP, Moliterno DJ. A critical appraisal of platelet glycoprotein IIb/IIIa inhibition. J Am Coll Cardiol 2000;36:2028-35.
3. Topol E, Moliterno D, Herrmann H, Powers E, Cohen D, Cohen E, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the preventive ischemic events with percutaneous coronary revascularization. N Engl J Med 2001;344:1888-94.
4. Tcheng JE, Kereiakes DJ, Lincoff AM, George BS, Kleiman NS, Sane DC, et al. Abciximab readministration: results of the ReoPro Readministration Registry. Circulation 2001;104:870-5.
5. Package insert. ReoPro (abciximab). Indianapolis: Eli Lilly, May 2001.
6. Package insert. Integrilin (eptifibatide). Cambridge, MA: Millennium Pharmaceuticals. May 2001.
7. Package insert. Aggrastat (tirofiban). Whitehouse Station, NJ: Merck and Company, May 2002.
8. Willerson JT. Golino P, Eidt J, Campbell WB, Buja LM. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation 1989:80:198-205.
9. Use of monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330:956-61.
10. Topol EJ, Califf RM, Weisman HF, Ellis SG, Tcheng JE, Worley S, et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. Lancet 1994:343:881-6.
11. Topol EJ, Lincoff AM, Kereiakes DJ, Kleiman NS, Cohen EA, Ferguson JJ, et al. Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization. Am J Med 2002;113:1-6.
12. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revasculatrization. The EPILOG Investigators. N Engl J Med 1997;336:1689-96.
13. Lincoff A, Tcheng J, Califf R, Kelley T, Timmis G, Kleiman N, et al. Sustained suppression of ischemic complications of coronary intervention by platelet GPIIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Circulation 1999:99:1951-8.
14. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. The CAPTURE Investigators. Lancet 1997;349:1429-35.
15. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Lancet 1998;352:87-92.
16. Topol E, Mark D, Lincoff A, Cohen E, Burton J, Kleiman N, et al. Outcomes at 1 year and economic implications of platelet glycoprotein IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. Lancet 1999;354:2019-24.
17. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Efficacy Study of Tirofiban for Outcomes and REstonis. Circulation 1997;96:1445-53.
18. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. The IMPACT-II Investigators. Lancet 1997;349:1422-8.
19. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. The ESPRIT Investigators. Lancet 2000;356:2037-44.
20. Rao AK, Pratt C, Berke A, Jaffe A, Ockene L, Schrieber TL, et al. Thrombolysis in myocardial infarction (TIMI) trial - phase I. Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase. J Am Coll Cardiol 1988;11:1-11.
21. Lincoff A, Califf R, Moliterno M, Ellis S, Ducas J, Kramer J, et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med 1999;341:319-27.
22. Kabbani SS, Aggarwal A, Terrien EF, DiBattiste PM, Sobel BE, Schneider DJ. Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions. Am J Cardiol 2002;89:647-50.
23. Moliterno DJ, Yakubov SJ, DiBattiste PM, Herrmann HC, Stone GW, Macaya C, et al. Outcomes at 6 months for the direct comparison of tirofiban and abciximab during percutaneous coronary revascularisation with stent placement: the TARGET follow-up study. Lancet 2002; 360:355-60.
24. Stone G, Moliterno D, Bertrand M, Neumann F, Herrmann H, Powers E, et al. Impact of clinical syndrome acuity on the differential response to two glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET trial (abstract). J Am Coll Cardiol 2002;39(suppl A):22A.
25. O'Shea J, Buller C, Cantor W, Chandler A, Cohen E, Cohen D, et al. Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA 2002;287:618-21.
26. Phillips D, Teng W, Arfsten A, Nannizzi-Alaimo L, White MM, Longhurst C, et al. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997;96:1488-94.
27. Tcheng J, Kereiakes D, Kleiman N, Talley J, Wang A, Weisman H, et al. Pbarmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high risk angioplasty. Circulation 1994;90:1757-64.
28. Labinaz M, Madan M, O'Shea JO, Kilaru R, Chin W, Pieper K, et al. Comparison of one-year outcomes following coronary artery stenting in diabetic versus nondiabetic patients (from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy [ESPRIT] Trial). Am J Cardiol 2002;90:585-90.
29. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. The PARAGON Investigators. Platelet IIb/IIIa Antagonism for the Reduction of Acute coronary syndrome events in a Global Organization Network. Circulation 1998;97:2386-95.
30. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators. N Engl J Med 1998;338:1498-505.
31. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998;338:1488-97.
32. Inhibition of the platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998;339:436-43. [erratum N Engl J Med 1998;339:415]
33. Simoons ML. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001;357:1915-24.
34. Randomized, placebo-controlled trial of titrated intravenous lamifiban for acute coronary syndromes. Circulation 2002;105:316-21.
35. Cannon CP, Weintraub WS, Demopoulos LA, Vicari R, Frey MJ, Lakkis N, et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001;344:1879-87.
36. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, et al. ACC/AHA guideline update for the management of pafients with unstable angina and non-ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). 2002. www.acc.org/clinical/guidelines/unstable/unstabte.pdf (accessed 2003 Jan 25).
37. Boersma E, Harrington RA, Moliterno DJ, White H, Simoons ML. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002; 359:189-98.
38. Ottervanger JP, Armstrong P, Barnathan ES, Boersma E, Cooper JS, Ohman EM, et al. Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS. Circulation 2003;107:437-42.
39. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators. Lancet 1999;354:708-15.
40. Wallentin L, Lagerqvist B, Husted S, Kontny F, Ståhle E, Swahn E. Outcome at 1 year after an invasive compared with a non-invasive strategy in unstable coronary-artery disease: the FRISC II invasive randomised trial. Lancet 2000;356:9-16.
41. Fox KA, Poole-Wilson PA, Henderson RA, Clayton TC, Chamberlain DA, Shaw TR, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Lancet 2002;360:743-51.
42. Kleiman NS, Ohman EM, Califf RM, George BS, Kereiakes D, Aguirre FV, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. J Am Coll Cardiol 1993; 22:381-9.
43. Ohman EM, Kleiman NS, Gacioch G, Worley SJ, Navetta FI, Talley JSD, et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with integrilin in acute myocardial infarction. Circulation 1997;95:846-54.
44. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. J Am Coll Cardiol 1998;32:2003-10.
45. van der Merkhof LFM, Zijlstra F, Olsson H, Grip L, Veen B, Bar FW, et al. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty: results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. J Am Coll Cardiol 1999;33:1528-32.
46. Antman EM, Giugliano RP, Gibson CM, McCabe CH, Coussement P, Kleiman NS, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction-14 (TIMI-14) trial. Circulation 1999;99:2720-32.
47. Antman EM, Gibson CM, de Lemos JA, Giugliano RP, McCabe CH, Coussement P, et al. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. Eur Heart J 2000; 21: 1944-53.
48. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. The SPEED Investigators. Circulation 2000:101:2788-94.
49. Giugliano RP, Roe MT, Staedische UZ. Restoration of epicardial and myocardial perfusion in acute ST-elevation myocardial infarction with combination eptifibatide and reduced-dose tenecteplase: dose-finding results from the INTEGRITI trial (abstract). Circulation 2001;104(suppl II):538.
50. Brener SJ, Zeyer U, Adgey AA, Vrobel TR, Ellis SG, Neuhaus KL, et al. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombosis in acute myocardial infarction (INTRO AMI) trial. J Am Coll Cardiol 2002;39:377-86.
51. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001; 357:1905-14.
52. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. ASSENT-3 investigators. Lancet 2001:358: 605-13.
53. Lincoff AM, Califf RM, van de Werf F, Willerson JT, White HD, Armstrong PW, et al. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced dose fibrinolytic therapy vs. conventional fibrinolytic therapy for acute myocardial infarction. JAMA 2002; 288:2130-5.
54. Antman EM, Louwerenburg HW, Baars HF, Wesdorp HC, Hamer B, Bassand JP, et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 trial. Circulation 2002;105:1642-9.
55. Lefkovits J, Ivanhoe RJ, Califf RM, Bergelson BA, Anderson KM, Stoner GL, et al. Effects of platelet glycoprotein IIb/IIIa receptor blockade by a chimeric monoclonal antibody (abciximab) on acute and six-month outcomes after percutaneous transluminal coronary angioplasty for acute myocardial infarction. Am J Cardiol 1996:77:1045-51.
56. Azar RR, McKay RG, Thompson PD, Hirst JA, Mitchell JF, Fram DB, et al. Abciximab in primary coronary angioplasty for acute myocardial infarction improves short- and medium-term outcomes. J Am Coll Cardiol 1998;32:1996-2002.
57. Neumann FJ, Blasini R, Schmitt C, Alt E, Dirschinger J, Gawaz M, et al. Effect of glycoprotein receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998;98:2695-701.
58. Neumann FJ, Kastrati A, Schmitt C, Blasini R, Hadamitzky M, Mehilli J, et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol 2000;35:915-21.
59. Schomig A, Kastrati A, Dirschinger J, Mehilli J, Schricke U, Pache J, et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute myocardial infarction. N Engl J Med 2000;343:385-91.
60. Giri S, Mitchel J, Azar RR, Kiernan FJ, Fram DB, McKay RG, et al. Results of primary percutaneous transluminal coronary angioplasty plus abciximab with or without stenting for acute myocardial infarction complicated by cardiogenic shock. Am J Cardiol 2002;89:126-31.
61. Brener S, Barr L, Burchenal J, Katz S, George B, Jones A, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation 1998:98:734-41.
62. Montalescot G, Barragan P, Wittenberg O, Ecollan P, Elhadad S, Villain P, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med 2001;344:1895-903.
63. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002;346:957-66.
64. van Hout BA, Bowman L, Zelinger DJ, Simoons ML. Costs and effects in therapy for acute coronary syndromes: the case of abciximab in high-risk patients undergoing percutaneous transluminal coronary angioplasty in the EPIC study. Evaluation of 7E3 for the Prevention of Ischemic Complications. Am Heart J 1998;135:S98-106.
65. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial. PRICE Investigators. Am Heart J 2001;141:402-9.
66. Zwart-van Rijkom JE, van Hout BA. Cost-efficacy in interventional cardiology; results from the EPISTENT study. Evaluation of Platelet IIb/IIIa Inhibitor For Stenting Trial. Eur Heart J 2001;22:1476-84.
67. Califf RM. Evaluating the costs and effectiveness of cardiovascular therapies: who cares about economic analyses? Stat Med 2002;21:2889-97.
68. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The CURE trial investigators. N Engl J Med 2001;345:494-502.
69. Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, et al. Effect of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001;358:527-33.
70. Cohen M, Demers C, Gurfinkle EP, Turpie AG, Fromell GJ, Goodman S, et al. A comparison of low-molecular-weight heparins with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337:447-52.
71. Cohen M, Theroux P, Weber S, Laramee P, Huynh T, Borzak S, et al. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol 1999;71:273-81.
72. Cohen M, Theroux P, Frey MJ, White JD, Borzak S, Weber S, et al. Antithrombotic Combination Using Tirofiban and Enoxaparin: the ACUTE II study (abstract). Circulation 2000;102(2 suppl):II-826.
73. Ferguson JJ, Antman EM, Bates ER, Cohen M, Every NR, Harrington RA, et al. The use of enoxaparin and IIb/IIIa antagonists in acute coronary syndromes, including PCI: final results of the NICE 3 study (abstract). J Am Coll Cardiol 2001;37:365A.
74. Young JJ, Kereiakes DJ, Grines CL. Low-molecular-weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 trials. J Invas Cardiol 2000;12(E suppl):E14-8, E18-25.
75. Kereiakes DJ, Kleiman NS, Fry E, Mwawasi G, Lengerich R, Maresh K, et al. Dalteparin in combination with abciximab during percutaneous coronary intervention. Am Heart J 2001;141:348-52.
76. Wallentin LC. GUSTO-IV ACS (Global Utilisation of Streptokinase and t-PA for Occluded coronary arteries Trial IV in Acute Coronary Syndromes): substudy comparing outcomes for the combination of abciximab with standard unfractionated heparin or low molecular weight heparin. Presented at: 22nd Congress of the European Society of Cardiology, Amsterdam, August 28, 2000.
77. Bhatt DL, Lincoff AM. Combined use of eptifibatide and enoxaparin in patients undergoing percutaneous coronary intervention: the results of the CRUISE trial. Circulation 2001;104:384-5.
78. Choussat R, Montalescot G, Collet JP, Gallois V, Sotirov Y, Drobinski G, et al. Low dose intravenous enoxaparin in elective percutaneous coronary intervention (abstract). Circulation 2001;104(2 suppl):II-706.
79. Mukherjee D, Mahaffey KW, Sparapani R, Dyke C, Roe MT, Moliterno DJ, et al. The promise of combined LMW heparin and platelet glycoprotein IIb/IIIa inhibition: results from PARAGON B (abstract). Circulation 2000;102(2 suppl):II-591.
80. Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003;289:853-63.
81. Smith SC, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, et al. ACC/AHA guidelines for percutaneous coronary intervention. J Am Coll Cardiol 2001;37:1-66.